RRMM Trials | Myeloma Trials

$NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma$

NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma

NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies RRMM Study Assessing Activity of Intravenous (IV)...

NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex

MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide,...

NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM

MagnetisMM-8 NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory...

NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) Pre-approval Single-patient Expanded Access for...

NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM

NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple...

NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM

NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM This is a randomized,...

NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)

NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide...

NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets

NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...

NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1

(SUCCESSOR-1) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone...